ABL1 (V299L)
Sign in to save this workspaceABL1 · Variant type: point · HGVS: p.V299L
Drug response on this variant
| # | Drug | Inhibition on variant | Residual | KISS |
|---|---|---|---|---|
| 1 | Vandetanib | 100.0% | 0.0% | 95.74 |
| 2 | Axitinib | 99.9% | 0.1% | 93.23 |
| 3 | Ponatinib | 99.9% | 0.1% | 78.23 |
| 4 | Dasatinib | 99.5% | 0.5% | 87.97 |
| 5 | Erdafitinib | 99.3% | 0.7% | 95.71 |
| 6 | Tivozanib | 98.9% | 1.1% | 92.42 |
| 7 | Fedratinib | 98.8% | 1.2% | 96.21 |
| 8 | Bosutinib | 97.5% | 2.5% | 87.22 |
| 9 | Repotrectinib | 97.5% | 2.5% | 84.21 |
| 10 | Pazopanib | 97.1% | 2.9% | 97.49 |
| 11 | Canertinib | 96.3% | 3.7% | 96.49 |
| 12 | Crizotinib | 96.1% | 3.9% | 91.39 |
| 13 | Nilotinib | 96.0% | 4.0% | 96.49 |
| 14 | Pacritinib | 95.7% | 4.3% | 88.64 |
| 15 | Selpercatinib | 95.5% | 4.5% | 96.72 |
| 16 | Nintedanib | 94.4% | 5.6% | 90.23 |
| 17 | Cabozantinib | 94.1% | 5.9% | 92.73 |
| 18 | Brigatinib | 93.9% | 6.1% | 82.96 |
| 19 | Entrectinib | 93.4% | 6.6% | 93.69 |
| 20 | Deucravacitinib | 93.4% | 6.6% | 98.99 |
| 21 | Pralsetinib | 93.3% | 6.7% | 93.43 |
| 22 | Dacomitinib | 87.3% | 12.7% | 97.99 |
| 23 | Lenvatinib | 85.6% | 14.4% | 97.74 |
| 24 | Dabrafenib | 82.6% | 17.4% | 94.74 |
| 25 | Gilteritinib | 79.0% | 21.0% | 88.97 |
Wild-type vs variant — drug response delta
Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).
| Drug | Variant inh | WT inh | Δ (variant − WT) |
|---|---|---|---|
| Vandetanib | 100.0% | 95.7% | +4.3% |
| Axitinib | 99.9% | 99.4% | +0.5% |
| Ponatinib | 99.9% | 100.0% | -0.1% |
| Dasatinib | 99.5% | 98.6% | +0.9% |
| Erdafitinib | 99.3% | 90.9% | +8.4% |
| Tivozanib | 98.9% | 95.8% | +3.0% |
| Fedratinib | 98.8% | 82.7% | +16.2% |
| Bosutinib | 97.5% | 99.7% | -2.2% |
| Repotrectinib | 97.5% | 93.6% | +3.9% |
| Pazopanib | 97.1% | 77.5% | +19.6% |
| Canertinib | 96.3% | 91.6% | +4.7% |
| Crizotinib | 96.1% | 97.0% | -0.9% |
| Nilotinib | 96.0% | 98.0% | -1.9% |
| Pacritinib | 95.7% | 92.0% | +3.6% |
| Selpercatinib | 95.5% | — | — |
| Nintedanib | 94.4% | 99.9% | -5.4% |
| Cabozantinib | 94.1% | — | — |
| Brigatinib | 93.9% | 82.8% | +11.1% |
| Entrectinib | 93.4% | — | — |
| Deucravacitinib | 93.4% | — | — |
| Pralsetinib | 93.3% | — | — |
| Dacomitinib | 87.3% | 80.8% | +6.4% |
| Lenvatinib | 85.6% | 76.3% | +9.3% |
| Dabrafenib | 82.6% | — | — |
| Gilteritinib | 79.0% | — | — |
Cancer associations
| Cancer | Organ | Source |
|---|---|---|
| haematopoietic_neoplasm_haematopoietic_and_lymphoid_tissue | Blood/Lymphatic System | ref |
| lymphoid_neoplasm_haematopoietic_and_lymphoid_tissue | Blood/Lymphatic System | ref |
| LICA-CN | Liver | ref |
Annotations
Sign in to read and post annotations.
Loading…
Served from saifudeen2026@1.0.0 · API 0.1.0 · 14.1ms